Xarelto Lawsuit Xarelto is a new type of blood thinner that was brought to market by Bayer and Johnson & Johnson in 2011. By 2013, sales of the medication had reached $1.3 billion, driven in part by marketing claims that touted Xarelto as a superior alternative to warfarin, which for decades was the standard anticoagulant treatment. Xarelto is now approved for a number of indications, including the prevention of blood clots in people with a heart rhythm disorder called atrial fibrillation, and to treat blood clots known as deep vein thrombosis and pulmonary embolism. Xarelto is also used to reduce the chances that people undergoing joint replacement surgery will develop a blood clot. In the few years it has been on the market, evidence has mounted that suggests claims of Xarelto’s superiority over warfarin may have been overblown. For one thing, there is currently no approved antidote to stop Xarelto Internal Bleeding that sometimes occurs with Xarelto. By contrast, warfarin bleeding can be stopped via the administration of vitamin K. The lack of a reversal agent means that internal bleeding – a risk with any anticoagulant – has the potential to be far more dangerous when it occurs in Xarelto patients. In 2014, the Institute for Safe Medicine Practices reported that adverse events associated with the use of Xarelto appeared to be on the rise. According to data from the U.S. Food & Drug Administration (FDA), the agency received a total of 680 Xarelto complications reports in the first quarter of 2013. For the first time, these reports outpaced those associated with Pradaxa, another blood thinner in the same class as Xarelto.
Xarelto Litigation By 2014, a number of Xarelto lawsuits had been filed on behalf of individuals who allegedly suffered incontrollable internal bleeding because of the medication. All of these complaints were brought on behalf of individual patients, or their families, as none of the plaintiffs had chosen to file a Xarelto class action lawsuit against the drug’s manufacturers. Among other things, the claims seek compensation for medical bills, lost wages, and other damages connected to the plaintiffs’ alleged injuries. Xarelto injury cases accuse Bayer and Johnson & Johnson of failing to warn patients and doctors about the risk of uncontrollable bleeding, particularly the lack of an approved reversal agent for such an occurrence. The complaints also allege that the drug makers wrongly marketed the medication as an improvement over warfarin, and assert that the benefits associated with Xarelto do not outweigh the risk of potentially life-threatening complications. Xarelto is a new type of blood thinner that was brought to market by Bayer and Johnson & Johnson in 2011. By 2013, sales of the medication had reached $1.3 billion, driven in part by marketing claims that touted Xarelto as a superior alternative to warfarin, which for decades was the standard anticoagulant treatment. Xarelto is now approved for a number of indications, including the prevention of blood clots in people with a heart rhythm disorder called atrial fibrillation, and to treat blood clots known as deep vein thrombosis and pulmonary embolism. Xarelto is also used to reduce the chances that people undergoing joint replacement surgery will develop a blood clot. In the few years it has been on the market, evidence has mounted that suggests claims of Xarelto’s superiority over warfarin may have been overblown. For one thing, there is currently no approved antidote to stop Xarelto Internal Bleeding that sometimes occurs with Xarelto. By contrast, warfarin bleeding can be stopped via the administration of vitamin K. The lack of a
reversal agent means that internal bleeding – a risk with any anticoagulant – has the potential to be far more dangerous when it occurs in Xarelto patients. In 2014, the Institute for Safe Medicine Practices reported that adverse events associated with the use of Xarelto appeared to be on the rise. According to data from the U.S. Food & Drug Administration (FDA), the agency received a total of 680 Xarelto complications reports in the first quarter of 2013. For the first time, these reports outpaced those associated with Pradaxa, another blood thinner in the same class as Xarelto.
Xarelto Litigation By 2014, a number of Xarelto lawsuits had been filed on behalf of individuals who allegedly suffered incontrollable internal bleeding because of the medication. All of these complaints were brought on behalf of individual patients, or their families, as none of the plaintiffs had chosen to file a Xarelto class action lawsuit against the drug’s manufacturers. Among other things, the claims seek compensation for medical bills, lost wages, and other damages connected to the plaintiffs’ alleged injuries. Xarelto injury cases accuse Bayer and Johnson & Johnson of failing to warn patients and doctors about the risk of uncontrollable bleeding, particularly the lack of an approved reversal agent for such an occurrence. The complaints also allege that the drug makers wrongly marketed the medication as an improvement over warfarin, and assert that the benefits associated with Xarelto do not outweigh the risk of potentially life-threatening complications. To know more about Xarelto Lawsuit please visit here: - http://www.thexareltolawsuit.com/